Open AccessMedicineBiology

M. Kantor, A. Abrantes, Andrea Estevez, A. Schiller, J. Torrent, J. Gascon, Robert Hernandez, C. Ochner

2018.12.2Canadian Journal of Gastroenterology and Hepatology

DOI: 10.1155/2018/4601420

tlooto Summary

This narrative review outlines the current knowledge regarding E. histolytica and the potential for developing a vaccine and offers insight in the development of a vaccine.

Abstract

Entamoeba histolytica is the responsible parasite of amoebiasis and remains one of the top three parasitic causes of mortality worldwide. With increased travel and emigration to developed countries, infection is becoming more common in nonendemic areas. Although the majority of individuals infected with E. histolytica remain asymptomatic, some present with amoebic colitis and disseminated disease. As more is learned about its pathogenesis and the host's immune response, the potential for developing a vaccine holds promise. This narrative review outlines the current knowledge regarding E. histolytica and E. dispar and insight in the development of a vaccine.

Citation format

KANTOR, M., et al. Entamoeba histolytica: Updates in clinical manifestation, pathogenesis, and vaccine development. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018.